Arvinas announced that it will present a poster at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place February 14-16 in San Francisco. The presentation will highlight the company’s lead product candidate, ARV-110, an oral androgen receptor-targeted PROTAC protein degrader for the treatment of men with metastatic castration-resistant prostate cancer. ARV-110 employs Arvinas’ proprietary PROTAC protein degradation technology.
https://thefly.com/landingPageNews.php?id=2861451
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.